MX365835B - Uso de akkermansia para tratar trastornos metabolicos. - Google Patents
Uso de akkermansia para tratar trastornos metabolicos.Info
- Publication number
- MX365835B MX365835B MX2015006234A MX2015006234A MX365835B MX 365835 B MX365835 B MX 365835B MX 2015006234 A MX2015006234 A MX 2015006234A MX 2015006234 A MX2015006234 A MX 2015006234A MX 365835 B MX365835 B MX 365835B
- Authority
- MX
- Mexico
- Prior art keywords
- akkermansia
- metabolic disorders
- treating metabolic
- fragments
- relates
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 3
- 241000702460 Akkermansia Species 0.000 title 1
- 241000702462 Akkermansia muciniphila Species 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere a Akkermansia muciniphila o fragmentos de ella para tratar un trastorno metabólico en un paciente que lo necesita. La presente invención también se refiere a una composición, una composición farmacéutica y un medicamento que contiene Akkermansia muciniphila o fragmentos de ella para tratar un trastorno metabólico. La presente invención también se refiere al uso de Akkerrnansia muciniphila o fragmentos de ella para promover la pérdida de peso en un paciente que lo necesita.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/073011 WO2014075745A1 (en) | 2012-11-19 | 2012-11-19 | Use of akkermansia for treating metabolic disorders |
PCT/EP2013/073972 WO2014076246A1 (en) | 2012-11-19 | 2013-11-15 | Use of akkermansia for treating metabolic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015006234A MX2015006234A (es) | 2015-10-29 |
MX365835B true MX365835B (es) | 2019-06-17 |
Family
ID=47257788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015006234A MX365835B (es) | 2012-11-19 | 2013-11-15 | Uso de akkermansia para tratar trastornos metabolicos. |
Country Status (14)
Country | Link |
---|---|
US (8) | US20150306152A1 (es) |
JP (2) | JP6426616B2 (es) |
KR (4) | KR20230121938A (es) |
CN (2) | CN104918626B (es) |
AU (1) | AU2013346726B2 (es) |
BR (1) | BR112015011403A2 (es) |
CA (1) | CA2891758C (es) |
DK (1) | DK2919796T3 (es) |
EA (2) | EA037315B1 (es) |
ES (1) | ES2871817T3 (es) |
HK (1) | HK1215375A1 (es) |
MX (1) | MX365835B (es) |
PT (1) | PT2919796T (es) |
WO (2) | WO2014075745A1 (es) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
EP2836224A4 (en) | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
WO2014075745A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
JP6637885B2 (ja) | 2013-07-21 | 2020-01-29 | ペンデュラム セラピューティクス, インコーポレイテッド | マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム |
US20150246081A1 (en) * | 2014-03-03 | 2015-09-03 | Shayne Kenneth Morris | Probiotics with methods for growth and use separately and in combination |
KR101740893B1 (ko) | 2014-05-20 | 2017-06-13 | 주식회사 엠디헬스케어 | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 |
JP6868562B2 (ja) | 2014-10-31 | 2021-05-19 | ペンデュラム セラピューティクス, インコーポレイテッド | 障害の微生物的処置および診断に関する方法および組成物 |
BR112017013274A2 (pt) | 2014-12-23 | 2018-02-06 | 4D Pharma Research Limited | polipeptídeo e imunomodulação |
SG11201704811YA (en) | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Immune modulation |
CN107980043B (zh) * | 2015-05-06 | 2021-09-24 | 瓦赫宁恩大学 | 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物 |
EP3292134B1 (en) | 2015-05-06 | 2020-10-21 | Wageningen Universiteit | Method of culturing akkermansia |
CN115364122A (zh) | 2015-06-15 | 2022-11-22 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
SI3307288T1 (sl) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Spojine, ki vsebujejo bakterijske seve |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
CN105106245A (zh) * | 2015-08-24 | 2015-12-02 | 上海交通大学医学院附属瑞金医院 | Akkermansia muciniphila BAA-835菌株的应用 |
CN105030841A (zh) * | 2015-08-24 | 2015-11-11 | 上海交通大学医学院附属瑞金医院 | Akkermansia muciniphila BAA-835菌株的应用 |
EP3943093A1 (en) * | 2015-09-10 | 2022-01-26 | Université catholique de Louvain | Use of pasteurized akkermansia for treating cancer |
EP3359171B1 (en) | 2015-10-05 | 2023-07-05 | Schweizerisches Forschungsinstitut für Hochgebirgsklima und Medizin in Davos | Use of akkermansia muciniphila for treating inflammatory conditions |
WO2017060491A1 (en) * | 2015-10-09 | 2017-04-13 | Biogaia Ab | Mucus thickness to prevent diseases |
CN105176822B (zh) * | 2015-10-23 | 2019-01-11 | 广州康泽医疗科技有限公司 | 一种人类肠道益生菌的优化分离方法 |
CN112569262A (zh) | 2015-11-20 | 2021-03-30 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
EP4257194A3 (en) | 2016-02-04 | 2023-12-20 | Universiteit Gent | Use of microbial communities for human and animal health |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
CN109069558A (zh) | 2016-03-04 | 2018-12-21 | 加利福尼亚大学董事会 | 微生物聚生体及其用途 |
CN108883139B (zh) | 2016-03-04 | 2022-04-26 | 4D制药有限公司 | 包含细菌菌株的组合物 |
JP7012377B2 (ja) | 2016-04-11 | 2022-02-14 | ヴァーヘニンゲン ユニバーシテイト | 新規な細菌種 |
EP3483256A4 (en) * | 2016-07-11 | 2019-12-04 | Korea Research Institute of Bioscience and Biotechnology | AKKERMANSIA MUCINIPHILA TRIBE WITH EFFECT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES OR METABOLIC DISEASES AND USE THEREOF |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
CN109874329B (zh) * | 2016-08-12 | 2023-08-29 | 深圳华大生命科学研究院 | 一种产丁酸栖粪杆菌及其培养方法和应用 |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
EP3558329B1 (en) * | 2016-12-20 | 2024-01-31 | The Regents of The University of California | Compositions and methods for inhibiting seizures |
WO2018187272A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
FR3065643B1 (fr) | 2017-04-26 | 2020-04-17 | Usines Chimiques D'ivry La Bataille (Ucib) | Composition nutraceutique et/ou pharmaceutique pour stimuler la production de beta-defensines de type 2 |
US10695386B2 (en) | 2017-05-11 | 2020-06-30 | Shayne K. Morris | Skin microbiome colonizer formulations and methods for use |
MA48939B1 (fr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
RS61210B1 (sr) | 2017-06-14 | 2021-01-29 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
JP6837581B2 (ja) | 2017-06-14 | 2021-03-03 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | Megasphaera属の細菌株を含む組成物及びその使用 |
TWI640314B (zh) * | 2017-08-22 | 2018-11-11 | 長庚生物科技股份有限公司 | 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途 |
TWI636788B (zh) * | 2017-08-28 | 2018-10-01 | 長庚生物科技股份有限公司 | 戈氏副擬桿菌用於抑制脂肪肝疾病之用途 |
WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
WO2019092896A1 (ja) * | 2017-11-08 | 2019-05-16 | アサヒグループホールディングス株式会社 | アッカーマンシア・ムシニフィラ増殖材 |
KR20200091438A (ko) * | 2017-11-30 | 2020-07-30 | 글리콤 에이/에스 | 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 |
AU2019229090A1 (en) * | 2018-03-02 | 2020-10-08 | Academisch Medisch Centrum | Fecal matter for prevention or treatment of autoimmune diseases |
EP3773645A4 (en) | 2018-04-10 | 2021-11-24 | Siolta Therapeutics, Inc. | MICROBIAL CONSORTIA |
US11291696B2 (en) | 2018-04-11 | 2022-04-05 | Shayne Morris | Pairing probiotics and prebiotics, methods for growth and use, separately and in combination |
US11168299B2 (en) | 2018-04-11 | 2021-11-09 | Shayne Morris | Pairing probiotics and prebiotics, methods for growth and use, separately and in combination |
KR102225939B1 (ko) * | 2018-04-19 | 2021-03-10 | 주식회사 고바이오랩 | 신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물 |
JP2021524230A (ja) * | 2018-05-15 | 2021-09-13 | デューク ユニバーシティ | アッカーマンシア種の遺伝子操作のためのシステムおよび方法 |
CN110496140B (zh) * | 2018-05-18 | 2022-05-31 | 瑞微(深圳)生物科技有限公司 | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或***的药物中的应用 |
US20210364526A1 (en) * | 2018-05-23 | 2021-11-25 | The Regents Of The University Of California | Methods of selecting subjects for treatment with metabolomic modulators |
EP3594321A1 (en) * | 2018-07-10 | 2020-01-15 | Université catholique de Louvain | Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof |
EP3840761A4 (en) * | 2018-08-20 | 2022-05-18 | Murdoch Children's Research Institute | BEHAVIORAL TREATMENT |
CN110964650B (zh) | 2018-09-27 | 2022-10-11 | 上海上药信谊药厂有限公司 | 一种用于预防和治疗代谢疾病的菌株及其应用 |
WO2020071660A1 (ko) * | 2018-10-01 | 2020-04-09 | 한국생명공학연구원 | 아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물 |
KR102197180B1 (ko) * | 2018-10-11 | 2020-12-31 | 주식회사 고바이오랩 | 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물 |
WO2020076136A2 (ko) * | 2018-10-11 | 2020-04-16 | 서울대학교산학협력단 | 아커만시아 뮤시니필라 균주 및 이의 용도 |
EP3669944B1 (en) | 2018-12-21 | 2023-12-20 | Salomon Amar | Use of akkermansia in the treatment of oral diseases |
CN114450399A (zh) * | 2019-05-02 | 2022-05-06 | 卢万天主教大学 | 用于治疗癌症的乳酸脱氢酶抑制剂多肽 |
JP7402629B2 (ja) * | 2019-07-19 | 2023-12-21 | 国立大学法人東京農工大学 | プロピオン酸菌発酵物含有組成物 |
TWI719549B (zh) * | 2019-07-22 | 2021-02-21 | 大江生醫股份有限公司 | 促進嗜黏蛋白艾克曼菌生長之益生質組合物 |
KR102128289B1 (ko) * | 2019-08-23 | 2020-06-30 | 주식회사 엔테로바이옴 | 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도 |
KR102128287B1 (ko) * | 2019-08-23 | 2020-06-30 | 주식회사 엔테로바이옴 | 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도 |
KR102520571B1 (ko) * | 2019-09-25 | 2023-04-13 | (주)헬스바이옴 | 암 치료를 위한 절대혐기성 인체 장내미생물 및 이의 용도 |
KR102397916B1 (ko) * | 2019-10-01 | 2022-05-17 | (주)헬스바이옴 | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 |
CN114786690A (zh) | 2019-10-07 | 2022-07-22 | 谢尔塔治疗公司 | 治疗性药物组合物 |
CN110698547B (zh) * | 2019-10-31 | 2023-01-03 | 南京农业大学 | 重组表达的阿克曼菌膜蛋白Amuc_1100及其应用 |
CN110786376A (zh) * | 2019-11-07 | 2020-02-14 | 中南大学湘雅医院 | 嗜黏蛋白艾克曼氏灭活菌在制备酸奶中的应用及酸奶的制备方法和应用 |
CN111202752A (zh) * | 2020-02-17 | 2020-05-29 | 上海市内分泌代谢病研究所 | 阿克曼氏菌组合物 |
CN111228315A (zh) | 2020-02-27 | 2020-06-05 | 上海上药信谊药厂有限公司 | 抗肿瘤组合物 |
CN111450233B (zh) * | 2020-03-19 | 2021-04-13 | 中国农业大学 | 一种微生物代谢产物在缓解糖脂代谢紊乱中的应用 |
CN115666627A (zh) * | 2020-03-25 | 2023-01-31 | 韩国生命工学研究院 | 源自嗜黏蛋白阿克曼菌的tars或其片段,及其用途 |
CN115698043A (zh) * | 2020-04-24 | 2023-02-03 | Ko生物技术有限公司 | 具有glp-1诱导活性的蛋白质变体及其用途 |
CN111996267A (zh) * | 2020-08-11 | 2020-11-27 | 康美华大基因技术有限公司 | 一种快速检测akk菌的荧光定量pcr引物组、试剂盒及其应用 |
KR102185827B1 (ko) * | 2020-08-26 | 2020-12-03 | 주식회사 엔테로바이옴 | 아커만시아 뮤시니필라 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물 |
BE1028339B1 (fr) * | 2020-11-09 | 2021-12-21 | A Mansia Biotech | Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert |
CN113116936A (zh) * | 2021-04-02 | 2021-07-16 | 上海市第六人民医院 | 嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用 |
CN113322202B (zh) * | 2021-05-31 | 2022-03-01 | 君维安(武汉)生命科技有限公司 | 一种阿克曼氏菌、其培养方法及其应用 |
JP7398714B2 (ja) * | 2021-06-28 | 2023-12-15 | 東栄新薬株式会社 | 医療・美容に応用可能なアッカーマンシア・ムシニフィラ増殖促進用組成物およびこれを含む医薬、飲食品、飼料 |
CN113862193B (zh) * | 2021-10-28 | 2023-12-22 | 江西普瑞森基因科技有限公司 | 一株嗜黏蛋白阿克曼氏菌及其在制备抗肿瘤药物中的应用 |
WO2023086620A1 (en) * | 2021-11-12 | 2023-05-19 | Gelesis, Llc | Compositions and methods for modulating the intestinal microbiome |
WO2023178194A2 (en) * | 2022-03-15 | 2023-09-21 | Pendulum Therapeutics, Inc. | Novel microbial composition and methods of use thereof |
CN114634892A (zh) * | 2022-03-24 | 2022-06-17 | 浙江省农业科学院 | 具有降血脂作用的益生菌组合物、制备方法及设备 |
CN114949002B (zh) * | 2022-06-08 | 2024-03-19 | 广州知易生物科技有限公司 | 嗜粘蛋白阿克曼菌在制备防治动脉粥样硬化的组合物中的应用 |
CN115252651A (zh) * | 2022-06-08 | 2022-11-01 | 广州知易生物科技有限公司 | 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物 |
CN114949003B (zh) * | 2022-06-08 | 2024-03-19 | 广州知易生物科技有限公司 | 嗜粘蛋白阿克曼菌及其应用和培养方法 |
CN116115647A (zh) * | 2022-06-08 | 2023-05-16 | 广州知易生物科技有限公司 | 嗜粘蛋白阿克曼菌在制备改善代谢综合征的药物组合物或保健品组合物中的应用 |
CN115463159A (zh) * | 2022-09-26 | 2022-12-13 | 暨南大学附属第一医院(广州华侨医院) | 一种阿克曼菌及阿克曼菌后生元在制备预防或治疗肝脏脂肪病变的药物或保健品中的应用 |
CN115747357A (zh) * | 2022-11-15 | 2023-03-07 | 迪辅乐生物(上海)有限公司 | 肠道嗜粘蛋白-阿克曼氏菌的检测试剂盒及其检测方法 |
CN116077536B (zh) * | 2023-03-17 | 2023-11-28 | 微康益生菌(苏州)股份有限公司 | 一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用 |
CN117603884B (zh) * | 2024-01-17 | 2024-03-26 | 广州同康生物科技有限公司 | 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
EP2030623A1 (en) * | 2007-08-17 | 2009-03-04 | Nestec S.A. | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
NZ602704A (en) | 2010-03-01 | 2015-01-30 | Agronomique Inst Nat Rech | Method of diagnostic of inflammatory bowel diseases |
EP2836224A4 (en) * | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS |
WO2014075745A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
-
2012
- 2012-11-19 WO PCT/EP2012/073011 patent/WO2014075745A1/en active Application Filing
-
2013
- 2013-11-15 AU AU2013346726A patent/AU2013346726B2/en active Active
- 2013-11-15 EA EA201500535A patent/EA037315B1/ru unknown
- 2013-11-15 KR KR1020237027149A patent/KR20230121938A/ko not_active Application Discontinuation
- 2013-11-15 ES ES13792006T patent/ES2871817T3/es active Active
- 2013-11-15 CA CA2891758A patent/CA2891758C/en active Active
- 2013-11-15 CN CN201380070847.0A patent/CN104918626B/zh active Active
- 2013-11-15 DK DK13792006.2T patent/DK2919796T3/da active
- 2013-11-15 EA EA202100040A patent/EA202100040A3/ru unknown
- 2013-11-15 KR KR1020157016539A patent/KR102297388B1/ko active IP Right Review Request
- 2013-11-15 MX MX2015006234A patent/MX365835B/es active IP Right Grant
- 2013-11-15 US US14/443,829 patent/US20150306152A1/en active Pending
- 2013-11-15 JP JP2015542276A patent/JP6426616B2/ja active Active
- 2013-11-15 CN CN202010521429.0A patent/CN111603488B/zh active Active
- 2013-11-15 BR BR112015011403-2A patent/BR112015011403A2/pt not_active Application Discontinuation
- 2013-11-15 WO PCT/EP2013/073972 patent/WO2014076246A1/en active Application Filing
- 2013-11-15 KR KR1020237017813A patent/KR102581171B1/ko active IP Right Grant
- 2013-11-15 KR KR1020217027510A patent/KR20210111871A/ko active Application Filing
- 2013-11-15 PT PT137920062T patent/PT2919796T/pt unknown
-
2016
- 2016-03-22 HK HK16103301.0A patent/HK1215375A1/zh unknown
-
2018
- 2018-10-25 JP JP2018200556A patent/JP2019048825A/ja active Pending
-
2019
- 2019-05-07 US US16/285,088 patent/US20190282630A1/en not_active Abandoned
- 2019-12-10 US US16/709,238 patent/US20200121737A1/en not_active Abandoned
- 2019-12-10 US US16/709,232 patent/US20200155616A1/en not_active Abandoned
- 2019-12-20 US US16/723,723 patent/US20200237833A1/en not_active Abandoned
- 2019-12-20 US US16/723,720 patent/US20200237832A1/en not_active Abandoned
-
2021
- 2021-06-25 US US17/358,333 patent/US20210322489A1/en active Pending
- 2021-09-03 US US17/466,516 patent/US20210393704A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015006234A (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
HRP20181364T8 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
IN2015DN03219A (es) | ||
IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
MX2015002292A (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r. | |
GB201106750D0 (en) | Novel compounds | |
NZ702663A (en) | Nuclear transport modulators and uses thereof | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
UA112549C2 (uk) | Частинки на основі поліакрилату, що містять активну сполуку | |
MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
PH12015500663A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
HK1197235A1 (zh) | 二氫吡唑、其藥物組合物及其治療生育障礙的用途 | |
EP2897621A4 (en) | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES, PAIN AND FEVER, SKIN DISEASES, CANCER AND PRECULTURAL INJURIES | |
MX337139B (es) | Composicion de miel con l-alanil-l-glutamina. | |
MX356052B (es) | Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion. | |
WO2013038200A3 (en) | Neurodevelopmental disorders | |
PH12015501179A1 (en) | Fixed dose pharmaceutical composition comprising mometasone and azelastine | |
MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. | |
NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
MX2015008454A (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |